MedTrace Logo

Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release Tablet

NCT03633487 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-02-28

Study results available
· View outcomes & findings →

Summary

Characterize and assess PK of guaifenesin in Mucinex® 1200 mg ER Bi-Layer Tablet

Conditions

  • Healthy Subjects

Interventions

DRUG

Mucinex®

Mucinex® 1200 mg ER Bi-Layer tablet

Sponsors & Collaborators

  • Reckitt Benckiser LLC

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-10-11
Primary Completion
2011-10-15
Completion
2011-10-15
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03633487 on ClinicalTrials.gov